Long‐term efficacy and safety of tildrakizumab for moderate‐to‐severe psoriasis: pooled analyses of two randomized phase III clinical trials (re SURFACE 1 and re SURFACE 2) through 148 weeks

Author:

Reich K.12,Warren R.B.3,Iversen L.4ORCID,Puig L.5,Pau‐Charles I.6,Igarashi A.7,Ohtsuki M.8,Falqués M.6,Harmut M.6,Rozzo S.9,Lebwohl M.G.10,Cantrell W.11,Blauvelt A.12ORCID,Thaçi D.13

Affiliation:

1. Centre for Translational Research in Inflammatory Skin Diseases Institute for Health Services Research in Dermatology and Nursing University Medical Center Hamburg‐Eppendorf Skinflammation® Center Hamburg Germany

2. Dermatologikum Berlin Berlin Germany

3. Dermatology Centre Salford Royal NHS Foundation Trust Manchester NIHR Biomedical Research Centre The University of Manchester Manchester U.K.

4. Department of Dermatology Aarhus University Hospital Aarhus Denmark

5. Hospital de la Santa Creu i Sant Pau Universitat Autònoma de Barcelona Barcelona Spain

6. Almirall R&D Barcelona Spain

7. NTT Medical Center Tokyo Tokyo Japan

8. Department of Dermatology Jichi Medical University Tochigi Japan

9. Sun Pharmaceuticals Princeton NJ U.S.A.

10. Icahn School of Medicine at Mount Sinai New York NY U.S.A.

11. Department of Dermatology University of Alabama at Birmingham Birmingham AL U.S.A.

12. Oregon Medical Research Center Portland OR U.S.A.

13. Institute and Comprehensive Centre for Inflammation Medicine University of Lübeck Lübeck Germany

Funder

Almirall R&D, Barcelona, Spain.

Publisher

Wiley

Subject

Dermatology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3